Corvus Pharmaceuticals, Inc.
CRVS
$7.07
-$0.75-9.54%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -11.27% | -3.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.04% | 3.41% | |||
| Operating Income | -3.04% | -3.41% | |||
| Income Before Tax | -26.99% | -152.64% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -26.99% | -152.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -26.99% | -152.64% | |||
| EBIT | -3.04% | -3.41% | |||
| EBITDA | -3.06% | -3.34% | |||
| EPS Basic | -19.26% | -148.81% | |||
| Normalized Basic EPS | -19.13% | -148.82% | |||
| EPS Diluted | -19.26% | 22.24% | |||
| Normalized Diluted EPS | -19.13% | -150.87% | |||
| Average Basic Shares Outstanding | 6.51% | 7.83% | |||
| Average Diluted Shares Outstanding | 6.51% | 3.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||